公司資料
BriaCell 股價、新聞與催化劑
- 股票代碼:
- BCTX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Canada
股票表現
4.11 USD (-3.97%)
收盤價
最後更新: 2026年10月1日
23.7M USD
市值
股價為何變動
截至 2026年10月1日，BCTX 下跌 3.97%，收於 $4.11。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Cancer Immunotherapy Developer
BriaCell Therapeutics develops immunotherapies intended to stimulate coordinated immune responses against cancer. Its programs combine allogeneic tumor-cell platforms with checkpoint inhibitors and other immune-modulating agents.
Bria-IMT in Metastatic Breast Cancer
Bria-IMT is an off-the-shelf whole-cell immunotherapy being evaluated with checkpoint blockade in metastatic breast cancer. The program has advanced into a pivotal Phase 3 study for patients who have exhausted multiple prior treatment options.
Personalized Off-the-Shelf Platform
The Bria-OTS and Bria-BRES approaches use a bank of engineered cell lines selected according to patient immune characteristics. This design seeks to preserve personalization while avoiding the manufacturing time required for fully patient-specific cell therapies.
Bria-BRES and Bria-PROS Expansion
Bria-BRES is being developed for breast cancer through a next-generation clinical program, while Bria-PROS extends the platform into prostate cancer. These programs broaden the company's pipeline beyond the lead Bria-IMT regimen.
Combination-Oriented Development
BriaCell's strategy is to pair its cellular immunotherapies with checkpoint inhibitors and other agents that may reinforce antitumor immune activity. The company retains responsibility for clinical development while using external manufacturing and clinical partners.
Biomarker-Guided Patient Selection
Clinical and translational work evaluates immune signatures and tumor characteristics associated with response. These biomarkers may help define the patients most likely to benefit from BriaCell's cellular regimens.
未來催化劑
- Initiation of the Phase 1/2a study of Bria-BRES+ following FDA clearance of the IND.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。